期刊文献+

血清降钙素原与C-反应蛋白水平在检测恶性肿瘤患者感染性疾病中的应用评价 被引量:25

Effectiveness of determination of levels of serum procalcitonin and C-reactive protein in diagnosis of infections in malignant tumor patients
原文传递
导出
摘要 目的探讨血清降钙素原(PCT)与C-反应蛋白(CRP)水平检测在恶性肿瘤患者感染诊断中的应用评价。方法选取医院2012年1月-2013年1月收治的50例恶性肿瘤感染患者作为观察组及26例恶性肿瘤非感染患者作为对照组,采用荧光免疫分析法和免疫比浊法分析两组患者的PCT、CRP及其阳性率。结果两组患者经过治疗后,观察组患者的PCT、CRP分别为(18.37±20.12)ng/ml、(46.49±32.52)mg/L,而对照组分别为(0.32±0.23)ng/ml、(5.14±5.29)mg/L,两组比较差异有统计学意义(t=4.560,6.419;P<0.05);两组患者经过治疗后,观察组患者的PCT、CRP的阳性率为92.0%、84.0%,对照组分别为11.5%、15.4%,两组比较差异有统计学意义(χ2=48.347,P<0.01;33.707,P<0.01)。结论 PCT与CRP均可作为患者早期感染的重要指标,而PCT水平还可对早期诊断、预后具有重要意义,值得临床推广使用。 OBJECTIVE To observe the effectiveness of determination of the levels of serum procalcitonin (PCT) and C-reactive protein (CRP)in diagnosis of infections in the malignant tumor patients.METHODS From Jan 2012 to Jan 2013,totally 50 malignant tumor patients complicated with infections were assigned as the observation group,and 26 malignant tumor patients without infections were set as the control group;the immunofluorescence assay and immunoturbidimetry assay were performed to analyze the levels of PCT and CRP as well as their positive rates.RESULTS After the treatment,the PCT level of the observation group was (1 8 .3 7 ± 2 0 .1 2 )ng/ml,the control group (0 .3 2 ± 0 .2 3 )ng/ml;the CRP level of the observation group was (4 6 .4 9 ± 3 2 .5 2 )mg/L,the control group (5 .1 4 ± 5 .2 9 )mg/L,there was significant difference between the two groups (t=4 .5 6 0 ,6 .4 1 9;P〈0 .0 5 ).After the treatment,the positive rate of PCT was 9 2 .0% in the observation group,1 1 .5% in the control group;the positive rate of CRP was 8 4 .0% in the observation group,1 5 .4% in the control group,there was significant difference between the two groups (χ^2=4 8 .3 4 7 ,P〈0 .0 1;3 3 .7 0 7 ,P〈0 .0 1 ).CONCLUSION Both PCT and CRP can serve as important indicators for the early infections,and the PCT level has great signifi-cance in the early diagnosis and prognosis,which is worthy to be promoted in the hospital.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2015年第1期16-18,共3页 Chinese Journal of Nosocomiology
基金 河北省卫生厅科技基金资助项目(20130538)
关键词 血清降钙素原 C-反应蛋白 恶性肿瘤 感染 Serum procalcitonin C-reactive protein Malignant tumor Infection
  • 相关文献

参考文献12

  • 1王顺,王永涛,贾征夫.恶性肿瘤患者医院感染病原菌分类及耐药性[J].中华医院感染学杂志,2013,23(22):5559-5561. 被引量:16
  • 2朱波,王英,陈艳华,陆一平,李晖.恶性肿瘤患者放化疗后医院感染分析[J].中华医院感染学杂志,2010,20(16):2421-2422. 被引量:59
  • 3Kim DY,Lee YS,Ahn S,et al.The usefulness of procalcitonin and C-reactive protein as early diagnostic markers of bacteremia in cancer patients with febrile neutropenia[J].Pediatr Infect Dis J,2011,43(3):176-180.
  • 4Yaegashi H,Izumi K,Kitagawa Y,et al.Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer:the role of procalcitonin[J].Int J Urol,2014,21(1):104-106.
  • 5熊明洁,范红,郭靓.80例脓毒血症患者血清降钙素原监测和预后评估的临床研究[J].重庆医学,2011,40(30):3076-3078. 被引量:62
  • 6刘英其.血清降钙素原在不同种类细菌脓毒症的早期鉴别诊断价值[J].中华医院感染学杂志,2013,23(3):500-502. 被引量:39
  • 7Denard J,Marolleau B,Jenny C,et al.C-reactive protein(CRP)is essential for efficient systemic transduction of recombinant adenoassociated virus vector 1(rAAV-1)and rAAV-6in mice[J].J Virol,2013,87(19):10784-10791.
  • 8de Martino M,Klatte T,Seemann C,et al.Validation of serum C-reactive protein(CRP)as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma(RCC)[J].BJU Int,2013,111(8):348-353.
  • 9Ingram PR,Inglis T,Moxon D,et al.Procalcitonin and C-reactive protein in severe 2009H1N1influenza infection[J].Intensive Care Med,2010,36(3):528-532.
  • 10Haran JP,Beaudoin FL,Suner S,et al.C-reactive protein as predictor of bacterial infection among patients with an influenza-like illness[J].Am J Emerg Med,2013,31(1):137-144.

二级参考文献47

  • 1林臻.恶性肿瘤患者放疗和(或)化疗后医院感染调查[J].广西医学院学报,2008,18(2):317-319. 被引量:12
  • 2高瑞英,盖红波.肿瘤放、化疗患者医院感染因素及对策[J].中华医院感染学杂志,2006,16(9):1041-1041. 被引量:19
  • 3Angus DC,Linde-Zwirble WT,Lidicker J,et al.Epidemiology of severe sepsis in the United States:an analysis of incidence,outcome and associated costs of care[J].Crit Care Med,2001,29:1303.
  • 4Russwurm S,Wiederhold M,Oberhoffer M,et al.Molecular aspects and natural source of procalcitonin[J].Clin Chem Lab Med,1999,37(8):789-797.
  • 5Linscheid P,Seboek D,Nylen ES,et al.In vitro and in vivo calcitonin I gene expression in parenchymal cells:a novel product of human adipose tissue[J].Endocrinology,2003,144:5578-5584.
  • 6Assicot M,Gendrel D,Carsin H,et al.High serum procalcitonin concentrations in patients with sepsis and infection[J].Lancet,1993,341:515-518.
  • 7Martin GS,Mannino DM,Eaton S.The epidemiology of sepsis in the United State from1979 through 2000[J].Nengl Med,2003,34(8):1546-1554.
  • 8Muller B,Becker KL,Schachinger H.Calcitonion precursors are reliable markers of sepsisin a medical intensive care uni[J].Crit Care Med,2000,28(4):977-983.
  • 9Han YY,Doughty La,Kofos D,et al.Procalcitonin is persistently increased among childrenwith poor outcome from bacterial sepsis[J].Pediatr Crit Care Med,2003,4(1):21-25.
  • 10Casad F,Asensio J,Arranz E,et al.Serum Procalcitonin in chilgren with suspected sepsis:Acomparison with C-reactive protein and neutrophil count[J].Pediatr Crit Care Med,2003,4(2):190-195.

共引文献254

同被引文献182

引证文献25

二级引证文献164

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部